HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target

-4.14%

ABSCI CORPORATION

ABSI

0.00

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Absci (NASDAQ: ABSI) with a Buy and maintains $7 price target.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Moderna Has Dosed The First Patient In A Phase 1/2 Study Of mRNA-2808, The Company's Investigational Mrna-based T-cell Engager For Relapsed Or Refractory Multiple Myeloma

Vir Biotechnology Completes Enrollment In ECLIPSE 1 Phase 3 Trial For Chronic Hepatitis Delta

INOVIO Completes Rolling BLA Submission For INO-3107 In Treatment Of RRP In Adults

UPDATE 1-Pfizer files second lawsuit against Metsera, Novo Nordisk

US Market Preview | MSPR Surges 161.4%; IREN Jumps 20% on $9.7B AI Deal With Microsoft; Morgan Stanley Boosts Oil Forecast Amid OPEC+ Pause

Marker Therapeutics To Present Data From Phase 1 APOLLO Study Investigating MT-601 In Patients With Relapsed B Cell Lymphomas At ASH 2025

A Look at Arcus Biosciences's Valuation Following $250 Million Equity Raise and Pipeline Progress

Krystal Biotech (KRYS): Margin Drop Challenges Bullish Growth Narratives Despite Strong Top-Line Outlook